ArticleTrials2019

The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial.

Takashi Nomura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.